Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print November 2, 2005, doi:10.1212/01.wnl.0000188670.38576.bd)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Video
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000188670.38576.bdv1
65/12/1967
65/12/1970    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frucht, S. J.
Right arrow Articles by Louis, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frucht, S. J.
Right arrow Articles by Louis, E. D.
Related Collections
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2005;65:1967-1969
© 2005 American Academy of Neurology
Brief Communications

A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor

S. J. Frucht, MD, W. C. Houghton, MD, Y. Bordelon, MD, PhD, P. E. Greene, MD and E. D. Louis, MD, MS

From the Columbia University Medical Center (Drs. Frucht, Greene, and Louis), New York, Jazz Pharmaceuticals (Dr. Houghton), Palo Alto, CA, and University of California Los Angeles Medical Center (Dr. Bordelon), Los Angeles.

Address correspondence and reprint requests to Dr Frucht, 710 W. 168 St., New York, NY 10032; e-mail: sf216{at}columbia.edu

The authors performed an open-label, rater-blinded, add-on study of sodium oxybate in 20 patients with ethanol-responsive myoclonus or essential tremor. Blinded ratings of videotaped examinations showed improvements in myoclonus at rest, stimulus-sensitive myoclonus, action myoclonus, functional performance, and postural and kinetic tremor. Tolerability was acceptable, and more than half of the patients chose to continue treatment after the trial. Double-blind placebo-controlled studies in these disorders are warranted.

This article was previously published in electronic format on November 2, 2005, as an Expedited E-Pub at www.neurology.org.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 27 issue to find the title link for this article.

Supported by RO1 NS042859 (E.D.L.) and Norman and Barbara Seiden (S.J.F.; Young Investigator Award).

Disclosure: Dr. Frucht has received consulting fees from Orphan Medical (now Jazz Pharmaceuticals) in amounts under $10,000. Dr. Houghton is an employee of Jazz Pharmaceuticals, the manufacturer of sodium oxybate. This study was not sponsored by Orphan Medical, and the company had no role in the design, implementation, or analysis of the data. Orphan Medical did provide drug without charge.

Received June 27, 2005. Accepted in final form September 22, 2005.




This article has been cited by other articles:


Home page
 PNHome page
F. B Nahab, E. Peckham, and M. Hallett
Essential tremor, deceptively simple ...
Practical Neurology, August 1, 2007; 7(4): 222 - 233.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.